The microtubule cytoskeleton is required for a G2 cell cycle delay in cancer cells lacking stathmin and p53

Cytoskeleton

Volumn 69, Issue 5, 2012, Pages 278-289

  Carney, Bruce K ^a   Caruso Silva, Victoria ^a   Cassimeris, Lynne ^a  

^a LEHIGH UNIVERSITY   (United States)

Author keywords

Acetylated tubulin; G2; Interphase duration; Microtubule; Stathmin

Indexed keywords

ALPHA TUBULIN; NOCODAZOLE; PACLITAXEL; PROTEIN P53; STATHMIN; VINBLASTINE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE G2 PHASE; CONFOCAL MICROSCOPY; CYTOSKELETON; DEPOLYMERIZATION; FEMALE; HELA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INTERPHASE; MICROTUBULE; MITOSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN ISOLATION; RNA INTERFERENCE; TRANSIENT TRANSFECTION; WESTERN BLOTTING;

APOPTOSIS; CENTROSOME; CYTOSKELETON; G2 PHASE; HELA CELLS; HUMANS; MICROTUBULES; MITOSIS; NOCODAZOLE; PACLITAXEL; PHOSPHORYLATION; RNA, SMALL INTERFERING; STATHMIN; TUBULIN; TUBULIN MODULATORS; TUMOR SUPPRESSOR PROTEIN P53; VINBLASTINE;

EID: 84861191606     PISSN: 19493584     EISSN: 19493592     Source Type: Journal    
DOI: 10.1002/cm.21024     Document Type: Article

References (63)

1. Ahn J, Murphy M, Kratowicz S, Wang A, Levine AJ, George DL. 1999. Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 induction. Oncogene 18(43): 5954-5958.
2. Alli E, Yang JM, Hait WN. 2007. Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene 26(7): 1003-1012.
3. Balestra FR, Jimenez J. 2008. A G2-phase microtubule-damage response in fission yeast. Genetics 180(4): 2073-2080.
4. Belletti B, Nicoloso MS, Schiappacassi M, Berton S, Lovat F, Wolf K, Canzonieri V, D'Andrea S, Zucchetto A, Friedl P, et al. 2008. Stathmin activity influences sarcoma cell shape, motility, and metastatic potential. Mol Biol Cell 19(5): 2003-2013.
5. Belletti B, Pellizzari I, Berton S, Fabris L, Wolf K, Lovat F, Schiappacassi M, D'Andrea S, Nicoloso MS, Lovisa S, et al. 2010. p27kip1 controls cell morphology and motility by regulating microtubule-dependent lipid raft recycling. Mol Cell Biol 30(9): 2229-2240.
6. Belmont LD, Mitchison TJ. 1996. Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. Cell 84(4): 623-631.
7. Bieche I, Lachkar S, Becette V, Cifuentes-Diaz C, Sobel A, Lidereau R, Curmi PA. 1998. Overexpression of the stathmin gene in a subset of human breast cancer. Br J Cancer 78(6): 701-709.
8. Blajeski AL, Phan VA, Kottke TJ, Kaufmann SH. 2002. G(1) and G(2) cell-cycle arrest following microtubule depolymerization in human breast cancer cells. J Clin Invest 110(1): 91-99.
9. Borgne A, Meijer L. 1996. Sequential dephosphorylation of p34(cdc2) on Thr-14 and Tyr-15 at the prophase/metaphase transition. J Biol Chem 271(44): 27847-27854.
10. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
11. Brattsand G. 2000. Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors. Br J Cancer 83(3): 311-318.
12. Brito DA, Rieder CL. 2006. Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Curr Biol 16(12): 1194-1200.
13. Budde PP, Kumagai A, Dunphy WG, Heald R. 2001. Regulation of Op18 during spindle assembly in Xenopus egg extracts. J Cell Biol 153(1): 149-158.
14. Bulinski JC, Richards JE, Piperno G. 1988. Posttranslational modifications of alpha tubulin: detyrosination and acetylation differentiate populations of interphase microtubules in cultured cells. J Cell Biol 106(4): 1213-1220.
15. Cambray-Deakin MA, Burgoyne RD. 1987. Acetylated and detyrosinated alpha-tubulins are co-localized in stable microtubules in rat meningeal fibroblasts. Cell Motil Cytoskeleton 8(3): 284-291.
16. Carney BK, Cassimeris L. 2010. Stathmin/oncoprotein 18, a microtubule regulatory protein, is required for survival of both normal and cancer cell lines lacking the tumor suppressor, p53. Cancer Biol Ther 9(9): 699-709.
17. Chen G, Wang H, Gharib TG, Huang CC, Thomas DG, Shedden KA, Kuick R, Taylor JM, Kardia SL, Misek DE, et al. 2003. Overexpression of oncoprotein 18 correlates with poor differentiation in lung adenocarcinomas. Mol Cell Proteomics 2(2): 107-116.
18. Curmi PA, Andersen SS, Lachkar S, Gavet O, Karsenti E, Knossow M, Sobel A. 1997. The stathmin/tubulin interaction in vitro. J Biol Chem 272(40): 25029-25036.
19. Friedrich B, Gronberg H, Landstrom M, Gullberg M, Bergh A. 1995. Differentiation-stage specific expression of oncoprotein 18 in human and rat prostatic adenocarcinoma. Prostate 27(2): 102-109.
20. Galmarini CM, Kamath K, Vanier-Viornery A, Hervieu V, Peiller E, Falette N, Puisieux A, Ann Jordan M, Dumontet C. 2003. Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics. Br J Cancer 88(11): 1793-1799.
21. Garrett S, Auer K, Compton DA, Kapoor TM. 2002. hTPX2 is required for normal spindle morphology and centrosome integrity during vertebrate cell division. Curr Biol 12(23): 2055-2059.
22. Gascoigne KE, Taylor SS. 2008. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 14(2): 111-122.
23. Holmfeldt P, Larsson N, Segerman B, Howell B, Morabito J, Cassimeris L, Gullberg M. 2001. The catastrophe-promoting activity of ectopic Op18/stathmin is required for disruption of mitotic spindles but not interphase microtubules. Mol Biol Cell 12(1): 73-83.
24. Holmfeldt P, Brattsand G, Gullberg M. 2002. MAP4 counteracts microtubule catastrophe promotion but not tubulin-sequestering activity in intact cells. Curr Biol 12(12): 1034-1039.
25. Holmfeldt P, Brannstrom K, Stenmark S, Gullberg M. 2006. Aneugenic activity of Op18/stathmin is potentiated by the somatic Q18→e mutation in leukemic cells. Mol Biol Cell 17(7): 2921-2930.
26. Holmfeldt P, Stenmark S, Gullberg M. 2007. Interphase-specific phosphorylation-mediated regulation of tubulin dimer partitioning in human cells. Mol Biol Cell 18(5): 1909-1917.
27. Howell B, Deacon H, Cassimeris L. 1999a. Decreasing oncoprotein 18/stathmin levels reduces microtubule catastrophes and increases microtubule polymer in vivo. J Cell Sci 112 (Part 21): 3713-3722.
28. Howell B, Larsson N, Gullberg M, Cassimeris L. 1999b. Dissociation of the tubulin-sequestering and microtubule catastrophe-promoting activities of oncoprotein 18/stathmin. Mol Biol Cell 10(1): 105-118.
29. Janke C, Kneussel M. 2010. Tubulin post-translational modifications: encoding functions on the neuronal microtubule cytoskeleton. Trends Neurosci 33(8): 362-372.
30. Johnsen JI, Aurelio ON, Kwaja Z, Jorgensen GE, Pellegata NS, Plattner R, Stanbridge EJ, Cajot JF. 2000. p53-mediated negative regulation of stathmin/Op18 expression is associated with G(2)/M cell-cycle arrest. Int J Cancer 88(5): 685-691.
31. Jordan MA, Thrower D, Wilson L. 1992. Effects of vinblastine, podophyllotoxin and nocodazole on mitotic spindles. Implications for the role of microtubule dynamics in mitosis. J Cell Sci 102 (Part 3): 401-416.
32. Jordan MA, Toso RJ, Thrower D, Wilson L. 1993. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 90(20): 9552-9556.
33. Koivusalo R, Krausz E, Helenius H, Hietanen S. 2005. Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA: opposite effect of siRNA in combination with different drugs. Mol Pharmacol 68(2): 372-382.
34. Kouzu Y, Uzawa K, Koike H, Saito K, Nakashima D, Higo M, Endo Y, Kasamatsu A, Shiiba M, Bukawa H, et al. 2006. Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis. Br J Cancer 94(5): 717-723.
35. Larsson N, Marklund U, Gradin HM, Brattsand G, Gullberg M. 1997. Control of microtubule dynamics by oncoprotein 18: dissection of the regulatory role of multisite phosphorylation during mitosis. Mol Cell Biol 17(9): 5530-5539.
36. Maddocks OD, Vousden KH. 2011. Metabolic regulation by p53. J Mol Med 89(3): 237-245.
37. Melhem R, Hailat N, Kuick R, Hanash SM. 1997. Quantitative analysis of Op18 phosphorylation in childhood acute leukemia. Leukemia 11(10): 1690-1695.
38. Mistry SJ, Bank A, Atweh GF. 2005. Targeting stathmin in prostate cancer. Mol Cancer Ther 4(12): 1821-1829.
39. Nakashima D, Uzawa K, Kasamatsu A, Koike H, Endo Y, Saito K, Hashitani S, Numata T, Urade M, Tanzawa H. 2006. Protein expression profiling identifies maspin and stathmin as potential biomarkers of adenoid cystic carcinoma of the salivary glands. Int J Cancer 118(3): 704-713.
40. Ngo TT, Peng T, Liang XJ, Akeju O, Pastorino S, Zhang W, Kotliarov Y, Zenklusen JC, Fine HA, Maric D, et al. 2007. The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas. J Natl Cancer Inst 99(8): 639-652.
41. Nguyen HL, Chari S, Gruber D, Lue CM, Chapin SJ, Bulinski JC. 1997. Overexpression of full- or partial-length MAP4 stabilizes microtubules and alters cell growth. J Cell Sci 110 (Part 2): 281-294.
42. Nishio K, Nakamura T, Koh Y, Kanzawa F, Tamura T, Saijo N. 2001. Oncoprotein 18 overexpression increases the sensitivity to vindesine in the human lung carcinoma cells. Cancer 91(8): 1494-1499.
43. Nylander K, Marklund U, Brattsand G, Gullberg M, Roos G. 1995. Immunohistochemical detection of oncoprotein 18 (Op18) in malignant lymphomas. Histochem J 27(2): 155-160.
44. Perdiz D, Mackeh R, Pous C, Baillet A. 2011. The ins and outs of tubulin acetylation: more than just a post-translational modification? Cell Signal 23(5): 763-771.
45. Piehl M, Cassimeris L. 2003. Organization and dynamics of growing microtubule plus ends during early mitosis. Mol Biol Cell 14(3): 916-925.
46. Piehl M, Tulu US, Wadsworth P, Cassimeris L. 2004. Centrosome maturation: measurement of microtubule nucleation throughout the cell cycle by using GFP-tagged EB1. Proc Natl Acad Sci USA 101(6): 1584-1588.
47. Price DK, Ball JR, Bahrani-Mostafavi Z, Vachris JC, Kaufman JS, Naumann RW, Higgins RV, Hall JB. 2000. The phosphoprotein Op18/stathmin is differentially expressed in ovarian cancer. Cancer Invest 18(8): 722-730.
48. Rieder CL, Cole R. 2000. Microtubule disassembly delays the G2-M transition in vertebrates. Curr Biol 10(17): 1067-1070.
49. Ringhoff DN, Cassimeris L. 2009a. Gene expression profiles in mouse embryo fibroblasts lacking stathmin, a microtubule regulatory protein, reveal changes in the expression of genes contributing to cell motility. BMC Genomics 10: 343.
50. Ringhoff DN, Cassimeris L. 2009b. Stathmin regulates centrosomal nucleation of microtubules and tubulin dimer/polymer partitioning. Mol Biol Cell 20(15): 3451-3458.
51. Schubart UK, Yu J, Amat JA, Wang Z, Hoffmann MK, Edelmann W. 1996. Normal development of mice lacking metablastin (P19), a phosphoprotein implicated in cell cycle regulation. J Biol Chem 271(24): 14062-14066.
52. Schulze E, Asai DJ, Bulinski JC, Kirschner M. 1987. Posttranslational modification and microtubule stability. J Cell Biol 105(5): 2167-2177.
53. Sellin ME, Holmfeldt P, Stenmark S, Gullberg M. 2008. Global regulation of the interphase microtubule system by abundantly expressed Op18/stathmin. Mol Biol Cell 19(7): 2897-2906.
54. Shi J, Orth JD, Mitchison T. 2008. Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5. Cancer Res 68(9): 3269-3276.
55. Srayko M, Kaya A, Stamford J, Hyman AA. 2005. Identification and characterization of factors required for microtubule growth and nucleation in the early C. elegans embryo. Dev Cell 9(2): 223-236.
56. Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA, Jr., Kinzler KW, Vogelstein B, Papadopoulos N. 2009. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci USA 106(10): 3964-3969.
57. Tarapore P, Fukasawa K. 2002. Loss of p53 and centrosome hyperamplification. Oncogene 21(40): 6234-6240.
58. Uetake Y, Sluder G. 2007. Cell-cycle progression without an intact microtuble cytoskeleton. Curr Biol 17(23): 2081-2086.
59. Wang Y, Ji P, Liu J, Broaddus RR, Xue F, Zhang W. 2009. Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy. Mol Cancer 8: 8.
60. Warren JC, Rutkowski A, Cassimeris L. 2006. Infection with replication-deficient adenovirus induces changes in the dynamic instability of host cell microtubules. Mol Biol Cell 17(8): 3557-3568.
61. Yuan RH, Jeng YM, Chen HL, Lai PL, Pan HW, Hsieh FJ, Lin CY, Lee PH, Hsu HC. 2006. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol 209(4): 549-558.
62. Yvon AM, Wadsworth P, Jordan MA. 1999. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 10(4): 947-959.
63. Zhang HZ, Wang Y, Gao P, Lin F, Liu L, Yu B, Ren JH, Zhao H, Wang R. 2006. Silencing stathmin gene expression by survivin promoter-driven siRNA vector to reverse malignant phenotype of tumor cells. Cancer Biol Ther 5(11): 1457-1461.